The GN01 study is a new clinical research study from Eli Lilly and Company. It will test if an investigational medicine (a medicine being studied) is safe and could reduce weight in people with obesity or overweight.
To be eligible for the study, you must be diagnosed with RSV and enrolled within 3 days of your symptoms starting.
This study will investigate the safety and efficacy of a new investigational medicine in adults who are living with obesity or excess weight with at least one weight-related medical condition (such as cardiovascular disease (CVD) or high blood pressure).
This study is evaluating an oral investigational medication (solriamfetol) in adults with BED. Solriamfetol is approved by the FDA for people who have excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea (OSA), which are sleep-related disorders. Solriamfetol is an investigational treatment for BED, meaning it has not yet been approved by any health authority for the treatment of BED.
Controlled Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants with Obesity or Overweight
We are looking for people who are affected by both hypertension and chronic kidney disease to participate in a research study to investigate a new experimental treatment. The research study is called EXPLORE-CKD
You may qualify if you:
- Have been diagnosed with hypertension and chronic kidney disease
- Are taking medication for hypertension
- Have abnormal kidney tests showing too much albumin (a type of protein) in your urine
Consider participating in the EXPLORE-CKD research study for a chance to contribute to research that may lead to more effective treatment options for high blood pressure and chronic kidney disease.
Choosing to participate in a clinical research study is an important decision. The information obtained from the EXPLORE-CKD study may help advance the treatment of future patients with high blood pressure and chronic kidney disease; and will provide important information about how well people respond to the study drug being investigated.
All clinical research studies are highly regulated to try to protect your safety and human rights. The research team can help explain this to you in further detail so that you are fully informed about the study before you decide whether you would like to participate.
What do I do next?
The EXPLORE-CKD Clinical Study is currently looking for interested study participants.
FOR MORE INFORMATION
Learn about the TargetTau-1 clinical study.
Are you or someone you know experiencing early symptoms of memory loss (mild cognitive impairment) or Alzheimer’s disease?
While there is no known cure for Alzheimer’s disease (AD), scientists have made huge progress in understanding AD and finding new routes for treatment, which can be achieved through clinical trials.
We are recruiting participants for the TargetTau-1 study. This clinical research study is testing a new, investigational medicine for mild cognitive impairment or mild early AD.
You may qualify for this study if you:
- Are 50-80 years old
- Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease, or have mild Alzheimer’s dementia
- Have a study partner with whom you spend at least 8 hours per week (such as a spouse, friend, or an adult child) who can attend some study visits with you during the study and provide follow-up information.
The study doctor will also check other eligibility requirements.
Participation in the study lasts about 2 years and requires regular visits to the research clinic to receive study drug and monitor your health and AD status. If you decide to take part in the study, all study-related drugs and procedures will be provided to you at no cost. Participation is voluntary and you would be able to leave the study at any point. To learn more and see if you are eligible, please contact: 786-772-0510
To learn more about this Alzheimer’s disease clinical study, visit: bmsclinicaltrials.com/TargetTau1
LAA2 is a new clinical research study from Eli Lilly and Company. It is testing if an investigational medicine (a medicine being studied) may help treat people with obesity or overweight and type 2 diabetes.
The Duo P201 Trial will evaluate the safety and immune response of 4 batches of an investigational combination vaccine aimed at preventing both seasonal flu and COVID-19 infections in adults 50 to 64 years of age.
Streptococcus pneumoniae is a common type of bacteria (germ) that can cause a wide variety of diseases, ranging from mild sinus and ear infections to more serious infections of the lungs, lining of the brain, or blood that require hospitalization and can be life-threatening. While anyone can get pneumococcal disease, adults over 50 have a higher risk of experiencing severe illness and are 8 times more likely to be hospitalized with pneumococcal pneumonia than younger adults.
According to the Centers for Disease Control and Prevention (CDC), getting vaccinated is the best way to help protect against pneumococcal disease. The CDC recommends that adults 65 years of age and older receive a pneumococcal vaccine as part of their routine vaccinations.
The vaccines available today protect against many strains of pneumococcal bacteria, but not all of them. That’s why we thought you may be interested in learning about Pfizer’s pneumococcal vaccine clinical trial designed to broaden protection against more bacterial strains.
We’re currently enrolling people who are:
- 50 to 64 years of age and have not previously received a pneumococcal vaccine.
- 65 years of age or older and have either not received a pneumococcal vaccine or have received the PNEUMOVAX® 23 vaccine more than 5 years ago.
Taking part in this clinical trial could potentially improve vaccine protection not only for you, but also others in the future.
Interested in joining this study? Here’s what you can expect if you take part:
- The study will last about one year, and you will attend at least 4 study visits.
- You will be randomly assigned to receive one dose of either the study vaccine or a licensed pneumococcal vaccine made by Pfizer (Prevnar 20®). You have an equal chance of being assigned to either vaccine group. There is no placebo (a shot with no active ingredient) in this study.
- Your safety is always our top priority. Our medical team will closely monitor your health while you are in the study. You can also leave this clinical trial at any time and for any reason.
- There is no cost to participate, and health insurance is not required. You will also be paid for completing study-related activities.
Please contact our team for more information. We’ll review the study’s requirements with you to help you decide if this clinical trial is a good fit for you.
Indago delivers community-based services for Miami and neighboring areas, driving advances in investigational research for new and improved drugs.
Working Hours
Monday-Friday 8:00 AM – 5:00 PM
Saturday (open if necessary)
Sunday (open if necessary)